| Market Capitalization (Millions $) |
7,997 |
| Shares
Outstanding (Millions) |
173 |
| Employees |
2,050 |
| Revenues (TTM) (Millions $) |
1,668 |
| Net Income (TTM) (Millions $) |
66 |
| Cash Flow (TTM) (Millions $) |
-170 |
| Capital Exp. (TTM) (Millions $) |
30 |
Business Description
Alkermes Plc is a biopharmaceutical company that specializes in developing innovative medicines to address unmet medical needs in large therapeutic categories. The company was founded in 1987 and is headquartered in Dublin, Ireland, with additional operations and research facilities in the United States and Europe.
Alkermes is focused on developing treatments for serious and chronic diseases including addiction, schizophrenia, opioid use disorder, and CNS disorders. The company offers a broad range of products and technologies that enable the development of novel therapies, including drug delivery systems, manufacturing technologies, and analytical capabilities.
The company's product portfolio includes VIVITROL for Alcohol Dependence, ARISTADA for Schizophrenia, RISPERDAL CONSTA for Schizophrenia and Bipolar Disorder, and BYDUREON for Type 2 Diabetes, among others. Alkermes has also been actively pursuing the development of new treatments for opioid addiction and overdose, including ALKS 5461 and ALKS 3831.
Alkermes has a highly experienced research and development team that is dedicated to advancing the science of drug development. The company is committed to investing in new technologies and platforms that can help to accelerate the pace of discovery and bring new treatments to patients in need.
Alkermes Plc is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "ALKS". The company has a strong track record of growth and continues to expand its global presence through strategic partnerships, acquisitions, and collaborations.
Company Address: Connaught House Dublin 4 0
Company Phone Number: 1-772-8000 Stock Exchange / Ticker: NASDAQ ALKS
|
3.85% 
151.17 %